TEDISAMIL SESQUIFUMARATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C19H32N2.3C4H4O4
Molecular Weight	925.158
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	3
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.C(C1CC1)N2CC3CN(CC4CC4)CC(C2)C35CCCC5.C(C6CC6)N7CC8CN(CC9CC9)CC(C7)C8%10CCCC%10

InChI

InChIKey=AZPYPAVFNGFTGB-VQYXCCSOSA-N

InChI=1S/2C19H32N2.3C4H4O4/c2*1-2-8-19(7-1)17-11-20(9-15-3-4-15)12-18(19)14-21(13-17)10-16-5-6-16;3*5-3(6)1-2-4(7)8/h2*15-18H,1-14H2;3*1-2H,(H,5,6)(H,7,8)/b;;3*2-1+

HIDE SMILES / InChI

Molecular Formula	C19H32N2
Molecular Weight	288.4708
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.fdanews.com/articles/102230-advisory-committee-recommends-no-approval-for-pulzium?v=preview | https://clinicaltrials.gov/ct2/show/NCT00126061 | http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con031129.pdf | https://www.ncbi.nlm.nih.gov/pubmed/14996649 | https://www.ncbi.nlm.nih.gov/pubmed/11527020

Tedisamil is an antiarrhythmic with additional anti-ischaemic properties, which acts via potassium channel blockade. This drug can be categorised as a class III antiarrhythmic agent due to its effects of action potential and QT interval prolongation in these patients. Although tedisamil has been shown to be an effective anti-ischaemic agent, with Phase III trials for angina pectoris now completed, the company are now pursuing the use of tedisamil for the treatment of atrial fibrillation, for which tedisamil is still in Phase II/III clinical trials. The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted not to recommend approval for Solvay Pharmaceuticals’ investigational anti-arrhythmic drug Pulzium (Tedisamil) and asked the company to give the FDA more information.

Originator

Approval Year

PubMed

Title	Date	PubMed
Recent advances in pharmacotherapy of atrial fibrillation.	2009-08	20523864
Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil.	2009-08	19604120
The transmembrane beta-subunits KCNE1, KCNE2, and DPP6 modify pharmacological effects of the antiarrhythmic agent tedisamil on the transient outward current Ito.	2009-06	19153714
Clinically important interaction between tedisamil and verapamil.	2009-05	19299533
Atrial fibrillation: from ion channels to bedside treatment options.	2008-10-17	19520377
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?	2008-09-22	18790110
Update on atrial fibrillation: part II.	2008-03	18383050
Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.	2008	18651412
New antiarrhythmic treatment of atrial fibrillation.	2007-07	17605649
Approach to the asymptomatic patients with Brugada syndrome.	2007-04-01	17538698
Do we need pharmacological therapy for atrial fibrillation in the ablation era?	2006-12	17340189
Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options.	2005-01-01	16943940
Trial finds new anti-arrhythmic, tedisamil, is superior to placebo for converting recent onset atrial fibrillation or atrial flutter.	2004-12	16379966
Effect of the antifibrillatory compound tedisamil (KC-8857) on transmembrane currents in mammalian ventricular myocytes.	2004-12	15579009
Tedisamil attenuates foetal transformation of myosin in the hypertrophied rat myocardium.	2004-11	15466442
Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter.	2004-07-07	15234416
Tedisamil: a new novel antiarrhythmic.	2004-02	14996649
Role of pharmacotherapy in Brugada syndrome.	2004-01-01	16943885
Theoretical possibilities for the development of novel antiarrhythmic drugs.	2004-01	14754422
Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation.	2004	14739742
Role of atrial fibrillation threshold evaluation on guiding treatment.	2003-10-01	16943922
Modulation of intracellular Ca(2+) concentration by tedisamil, a class III antiarrhythmic agent, in isolated heart preparation.	2003-08-22	12888119
Tedisamil and lidocaine enhance each other's antiarrhythmic activity against ischaemia-induced arrhythmias in rats.	2003-08	12922925
Tedisamil in coronary disease: additional benefits in the therapy of atrial fibrillation?	2003-06	12746750
Antiarrhythmic drug therapy of atrial fibrillation: focus on new agents.	2003-06	12746749
Atrial fibrillation: emerging possibilities for drug treatment: an overview of current opportunities and recent developments.	2003-06	12746746
Bertosamil blocks HERG potassium channels in their open and inactivated states.	2002-09	12208779
Tedisamil blocks BK-type Ca(2+)-dependent K(+) channels and modulates action potentials in rat hippocampal neurons.	2002-02-15	11825675
New antiarrhythmic drugs for the treatment of atrial fibrillation.	2002-02	11916001
Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models.	2001-10	11699522
Newer antiarrhythmic drugs.	2001-08-23	11516042
Effects of tedisamil on cardiovascular tissues isolated from normo- and hypertensive rats.	2001-07	11584333
Transgenic mice overexpressing human KvLQT1 dominant-negative isoform. Part II: Pharmacological profile.	2001-05	11334836
Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence.	2001-04	11264243
Tedisamil (Solvay).	2001-01	11527020
Tedisamil: master switch of nature?	2001-01	11116286
Dispersion of cell-to-cell uncoupling precedes low K+-induced ventricular fibrillation.	2001	11521735
Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7.	1998-03-06	9488722

Sample Use Guides

In Vivo Use Guide

The recommended dose is 0.32 mg/kg

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:18:15 GMT 2025` Edited by `admin` on `Mon Mar 31 18:18:15 GMT 2025`
Record UNII	Y4HRG433UU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PULZIUM

Preferred Name

English

TEDISAMIL SESQUIFUMARATE

Official Name

English

KC-8857 SESQUIFUMARATE

Code

English

TEDISAMIL SESQUIFUMARATE [USAN]

Common Name

English

Tedisamil sesquifumarate [WHO-DD]

Common Name

English

SPIRO(CYCLOPENTANE-1,9'-(3,7)DIAZABICYCLO(3.3.1)NONANE), 3',7'-BIS(CYCLOPROPYLMETHYL)-, (2E)-2-BUTENEDIOATE (2:3)

Common Name

English

TEDISAMIL SESQUIFUMARATE [MI]

Common Name

English

BIS(3',7'-BIS(CYCLOPROPYLMETHYL)SPIRO(CYCLOPENTANE-1,9'-(3,7)DIAZABICYCLO(3.3.1)NONANE))DIHYDROGEN TRIS((2E-BUT-2-ENEDIOATE)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C93038